Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Assessing the Impact of Marginalization on Survival for Patients Undergoing Allogeneic Stem Cell Transplant in Ontario, Canada

Adam Suleman, Sho Podolsky, Ning Liu, Kelvin KW Chan, Sumedha Arya, Lisa Hicks, Matthew C. Cheung, Anca Prica

Blood (2023) 142 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2023-185351

Published: 2023

Journal Articles

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Rena Buckstein, Olivia Lopes, Amy J. M. McNaughton, Matthew C. Cheung, Lee Mozessohn, Lisa Chodirker, Kevin Imrie, Neil Berinstein, Signy Chow, Gillian Kupakuwana-Suk, Anne Parmentier, Prasha Sasitharakumar, Hubert Tsui, Liying Zhang, Michael J. Rauh

Blood (2023) 142 (Supplement 1): 442.

https://doi.org/10.1182/blood-2023-187778

Published: 2023

Journal Articles

Outcomes of Transplant-Eligible and Transplant-Ineligible Patients with Mantle Cell Lymphoma in Ontario, Canada

Adam Suleman, Zharmaine Ante, Ning Liu, Michael Crump, Kelvin KW Chan, Matthew C. Cheung, Anca Prica

Blood (2023) 142 (Supplement 1): 1665.

https://doi.org/10.1182/blood-2023-177788

Published: 2023

Journal Articles

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

Diego Villa, Jean-Francois Larouche, Matthew C. Cheung, Mary-Margaret Keating, Katherine Zukotynski, Petter Tonseth, Samantha Mayo, Robert Laister, David W. Scott, John Kuruvilla

Blood (2023) 142 (Supplement 1): 3042.

https://doi.org/10.1182/blood-2023-179375

Published: 2023

Journal Articles

Assessing the Impact of Marginalization on Survival for Patients Undergoing Autologous Stem Cell Transplant in Ontario, Canada

Adam Suleman, Sho Podolsky, Ning Liu, Kelvin KW Chan, Sumedha Arya, Lisa Hicks, Matthew C. Cheung, Anca Prica

Blood (2023) 142 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2023-173609

Published: 2023

Journal Articles

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Blood (2023) 142 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2023-189296

Published: 2023

Journal Articles

Indolent Lymphoma Care Delivery and Outcomes during the COVID-19 Pandemic in Ontario, Canada

Inna Gong, Anca Prica, Zharmaine Ante, Andrew Calzavara, Monika Krzyzanowska, Simron Singh, Adam Suleman, Matthew C. Cheung, Michael Crump

Blood (2023) 142 (Supplement 1): 7386.

https://doi.org/10.1182/blood-2023-181296

Published: 2023

Journal Articles

Phase-Specific Costs of Care in Hematological Malignancies in Ontario, Canada

Judy Truong, Soo Jin Seung, Christoffer Dharma, Stephanie Y Cheng, Craig Earle, Simron Singh, Nicole Mittman, Matthew C. Cheung

Blood (2022) 140 (Supplement 1): 2165–2166.

https://doi.org/10.1182/blood-2022-168006

Published: 2022

Journal Articles

The Impact of Drug Interactions on Outcomes in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia in Routine Clinical Care: A Population-Based Cohort Study

Tuan Hoang, Matthew C. Cheung, Kelvin KW Chan, Cindy Lau, Ning Liu, Husam Abdel-Qadir, David Juurlink, Anca Prica, Alia Thawer, Abi Vijenthira, Lee Mozessohn

Blood (2022) 140 (Supplement 1): 2159–2160.

https://doi.org/10.1182/blood-2022-158768

Published: 2022

Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2021-154729

Published: 2021

Journal Articles

Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis

Matthew C. Cheung, MDMSc, Irina Amitai, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-140577

Published: 2020

Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-136692

Published: 2020

Journal Articles

Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study

Abi Vijenthira, MD, Lee Mozessohn, MD, Chenthila Nagamuthu, MPH, Ning Liu, Danielle Blunt, MD, Shabbir Alibhai, MD MSc, Anca Prica, MD, Matthew C. Cheung, MDMSc

Blood (2020) 136 (Supplement 1): 34–37.

https://doi.org/10.1182/blood-2020-140585

Published: 2020

Journal Articles

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Lee Mozessohn, MD FRCPC, Matthew C. Cheung, MD SM, FRCPC, Saber Fallahpour, PhD, Tripat Gill, MSc PH, Asmaa Maloul, PhD, Liying Zhang, PhD, Olivia Lau, Rena Buckstein, MD

Blood (2016) 128 (22): 4338.

https://doi.org/10.1182/blood.V128.22.4338.4338

Published: 2016

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis

Abi Vijenthira, MD, Matthew C Cheung, MD, Chai Wye Phua, MD, Kelvin Chan, Joanna Graczyk, MD, Rena Buckstein, MD, Anca Prica, MD

Blood (2016) 128 (22): 1183.

https://doi.org/10.1182/blood.V128.22.1183.1183

Published: 2016

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Matthew C Cheung, MD SM, FRCPC, Nicole Mittmann, PhD, Craig Earle, MD MSc., Farah Rahman, Ning Liu, Simron Singh, MD MPH, FRCPC

Blood (2016) 128 (22): 692.

https://doi.org/10.1182/blood.V128.22.692.692

Published: 2016

Journal Articles

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Matthew C Cheung, MD SM, FRCPC, Sierra Cheng, Erica McDonald, Vanessa Arciero, Mahin Qureshi, Kelvin Chan

Blood (2016) 128 (22): 3578.

https://doi.org/10.1182/blood.V128.22.3578.3578

Published: 2016

Journal Articles

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Daniel Jacobson, BSc. (C), Nicholas Chiu, MD(C), Matthew C. Cheung, MD SM, FRCPC, Robert Fowler, MD MDM, M.Sc., Rena Buckstein, MD

Blood (2016) 128 (22): 3595.

https://doi.org/10.1182/blood.V128.22.3595.3595

Published: 2016

NARROW

Assessing the Impact of Marginalization on Survival for Patients Undergoing Allogeneic Stem Cell Transplant in Ontario, Canada

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Outcomes of Transplant-Eligible and Transplant-Ineligible Patients with Mantle Cell Lymphoma in Ontario, Canada

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

Assessing the Impact of Marginalization on Survival for Patients Undergoing Autologous Stem Cell Transplant in Ontario, Canada

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Indolent Lymphoma Care Delivery and Outcomes during the COVID-19 Pandemic in Ontario, Canada

Phase-Specific Costs of Care in Hematological Malignancies in Ontario, Canada

The Impact of Drug Interactions on Outcomes in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia in Routine Clinical Care: A Population-Based Cohort Study

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only